Drugmaker GlaxoSmithKline issued a recall Wednesday for more than 430,000 bottles of Excedrin due to a manufacturing defect that may have left holes in the bottom of the painkiller bottles.
The full recall includes many of the company’s over-the-counter aspirin- and acetaminophen-based products sold nationwide between March 2018 and September 2020.
No injuries or incidents have been reported, but the products – sold under the brand names Excedrin Migraine Caplets, Excedrin Migraine Geltabs, Excedrin Extra Strength Caplets, Excedrin PM Headache Caplets, and Excedrin Tension Headache Caplets – have been deemed to violate the Poison Prevention Packaging Act. The act mandates childproof packaging for a lengthy list of potentially hazardous household products, including over-the-counter and prescription drugs.
According to the statement issued by GlaxoSmithKline, the potentially compromised Excedrin bottles were supplied by a third-party manufacturer and were sold nationwide and online. Undamaged bottles can be kept and used as directed, and those with holes can be returned to GlaxoSmithKline for a full refund.
Cox Media Group
/cloudfront-us-east-1.images.arcpublishing.com/cmg/7QOJU3BNCJERBNKJC5LWTBYFLU.png)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/GEJEVZNRS5FHZJE6RCXK4FXI4U.png)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/APEADNSYNZAGBGLVVRRZFDKRBA.jpg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/P3JKFWGXZ5F4FPTPI2FC4EQ5IQ.jpeg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/TVOB5USH2MWPBCK6GIQSLQKRIU.jpg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/JD6R4A73HVHGVL4AXVJB5EAMUU.jpg)